Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Incyte Corporation - Common Stock (NQ:INCY)

86.96 UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EDT, Sep 3, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Incyte Corporation - Common Stock

< Previous 1 2 3 4 5 6 7 8 9 Next >
Incyte Launches HS TRUTHS to Spotlight the True Lived Experience of Hidradenitis Suppurativa
From Incyte
Via Business Wire
Incyte Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
From Incyte
Via Business Wire
Incyte Announces the Appointment of Soni Basi as Executive Vice President and Chief Human Resources Officer
From Incyte
Via Business Wire
Incyte to Present at Upcoming Investor Conferences
From Incyte
Via Business Wire
Incyte Announces Departure of Chief Financial Officer Christiana Stamoulis
From Incyte
Via Business Wire
Incyte Reports 2025 Second Quarter Financial Results and Provides Updates on Key Clinical Programs
From Incyte
Via Business Wire
Incyte To Present Initial Data for its TGFβR2×PD-1-directed Bispecific Antibody (INCA33890) and its Selective Inhibitor of G12D-mutated KRAS (INCB161734) at the European Society of Medical Oncology (ESMO) Congress 2025
From Incyte
Via Business Wire
Incyte to Report Second Quarter Financial Results
From Incyte
Via Business Wire
Incyte Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
From Incyte Corporation
Via Business Wire
Incyte Appoints Bill Meury Chief Executive Officer; Hervé Hoppenot to Retire
From Incyte
Via Business Wire
Update on FDA Review of Ruxolitinib Cream (Opzelura®) for Children Ages 2-11 with Atopic Dermatitis
From Incyte
Via Business Wire
Incyte Announces FDA Approval of Monjuvi® (tafasitamab-cxix) in Combination with Rituximab and Lenalidomide for Patients with Relapsed or Refractory Follicular Lymphoma
From Incyte
Via Business Wire
QIAGEN and Incyte Announce Precision Medicine Collaboration to Develop Companion Diagnostics for Patients With Mutant CALR-expressing Myeloproliferative Neoplasms (MPNs)
From QIAGEN N.V.
Via Business Wire
Positive Late-Breaking Data for Incyte’s First-in-Class mutCALR-targeted therapy INCA033989 in Essential Thrombocythemia Presented at EHA2025
From Incyte
Via Business Wire
Phase 3 Data for Incyte’s Retifanlimab (Zynyz®) in Patients with Squamous Cell Carcinoma of the Anal Canal (SCAC) Published in The Lancet
From Incyte
Via Business Wire
Incyte Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Incyte
Via Business Wire
Incyte Announces Multiple Presentations, Including New Late-Breaking Data for its mutCALR-Directed Monoclonal Antibody (INCA033989), Accepted for Presentation at EHA 2025
From Incyte
Via Business Wire
Incyte to Present at Upcoming Investor Conference
From Incyte
Via Business Wire
Incyte Announces FDA Approval of Zynyz® (retifanlimab-dlwr) Making it the First and Only Approved First-Line Treatment for Advanced Anal Cancer Patients in the United States
From Incyte
Via Business Wire
Incyte Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Incyte
Via Business Wire
Incyte to Present at Upcoming Investor Conference
From Incyte
Via Business Wire
Incyte Reports 2025 First Quarter Financial Results and Provides Updates on Key Clinical Programs
From Incyte
Via Business Wire
Incyte to Highlight Early-Stage Oncology Data at American Association for Cancer Research Annual Meeting 2025
From Incyte
Via Business Wire
Incyte to Showcase New Data from its Oncology Portfolio at 2025 American Society of Clinical Oncology (ASCO) Annual Meeting
From Incyte
Via Business Wire
Incyte to Report First Quarter Financial Results
From Incyte
Via Business Wire
Incyte Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Incyte
Via Business Wire
Incyte Announces Positive Topline Results From Two Phase 3 Clinical Trials of Povorcitinib in Patients With Hidradenitis Suppurativa
From Incyte
Via Business Wire
Incyte Announces Results of Phase 3 Clinical Trials Evaluating Ruxolitinib Cream 1.5% (Opzelura®) in Patients with Prurigo Nodularis (PN) at 2025 American Academy of Dermatology Annual Meeting
From Incyte
Via Business Wire
Incyte Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Incyte
Via Business Wire
Incyte to Unveil New Data from its Dermatology Portfolio at 2025 American Academy of Dermatology (AAD) Annual Meeting
From Incyte
Via Business Wire
< Previous 1 2 3 4 5 6 7 8 9 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.